Your browser doesn't support javascript.
Letter: rationalising aminosalicylates in inflammatory bowel disease-authors' reply.
Chapman, Thomas P; Frias Gomes, Catarina; Louis, Edouard; Colombel, Jean-Frédéric; Satsangi, Jack.
  • Chapman TP; Translational Gastroenterology Unit, Nuffield Department of Experimental Medicine, University of Oxford, Oxford, UK.
  • Frias Gomes C; Department of Gastroenterology, Western Sussex Hospitals NHS Foundation Trust, Worthing, UK.
  • Louis E; Surgical Department, Gastroenterology Division, Hospital Beatriz Ângelo, Loures, Portugal.
  • Colombel JF; Department of Gastroenterology, CHU Liège University Hospital, Liège, Belgium.
  • Satsangi J; The Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.
Aliment Pharmacol Ther ; 52(10): 1621, 2020 11.
Article in English | MEDLINE | ID: covidwho-908904
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Inflammatory Bowel Diseases / Mesalamine Limits: Humans Language: English Journal: Aliment Pharmacol Ther Journal subject: Pharmacology / Gastroenterology / Drug Therapy Year: 2020 Document Type: Article Affiliation country: Apt.16113

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Inflammatory Bowel Diseases / Mesalamine Limits: Humans Language: English Journal: Aliment Pharmacol Ther Journal subject: Pharmacology / Gastroenterology / Drug Therapy Year: 2020 Document Type: Article Affiliation country: Apt.16113